Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
Matulonis, Ursula × Vergote, Ignace Backes, Floor Martin, Lainie P McMeekin, Scott Birrer, Michael Campana, Frank Xu, Yi Egile, Coumaran Ghamande, Sharad #
Gynecologic Oncology vol:136 issue:2 pages:246-53
Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide 3-kinase (PI3K) inhibitors are investigational treatment options in this setting. This study evaluated the efficacy and safety of the PI3K inhibitor pilaralisib (SAR245408; XL147) in advanced or recurrent endometrial carcinoma.